These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Djojosubroto MW; Chin AC; Go N; Schaetzlein S; Manns MP; Gryaznov S; Harley CB; Rudolph KL Hepatology; 2005 Nov; 42(5):1127-36. PubMed ID: 16114043 [TBL] [Abstract][Full Text] [Related]
3. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Dikmen ZG; Gellert GC; Jackson S; Gryaznov S; Tressler R; Dogan P; Wright WE; Shay JW Cancer Res; 2005 Sep; 65(17):7866-73. PubMed ID: 16140956 [TBL] [Abstract][Full Text] [Related]
4. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma. Hu Y; Bobb D; He J; Hill DA; Dome JS Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748 [TBL] [Abstract][Full Text] [Related]
5. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619 [TBL] [Abstract][Full Text] [Related]
6. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells. Gomez-Millan J; Goldblatt EM; Gryaznov SM; Mendonca MS; Herbert BS Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):897-905. PubMed ID: 17175117 [TBL] [Abstract][Full Text] [Related]
7. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Gellert GC; Dikmen ZG; Wright WE; Gryaznov S; Shay JW Breast Cancer Res Treat; 2006 Mar; 96(1):73-81. PubMed ID: 16319992 [TBL] [Abstract][Full Text] [Related]
8. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Goldblatt EM; Gentry ER; Fox MJ; Gryaznov SM; Shen C; Herbert BS Mol Cancer Ther; 2009 Jul; 8(7):2027-35. PubMed ID: 19509275 [TBL] [Abstract][Full Text] [Related]
10. Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent. Gryaznov SM; Jackson S; Dikmen G; Harley C; Herbert BS; Wright WE; Shay JW Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1577-9. PubMed ID: 18066830 [TBL] [Abstract][Full Text] [Related]
11. Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Akiyama M; Hideshima T; Shammas MA; Hayashi T; Hamasaki M; Tai YT; Richardson P; Gryaznov S; Munshi NC; Anderson KC Cancer Res; 2003 Oct; 63(19):6187-94. PubMed ID: 14559802 [TBL] [Abstract][Full Text] [Related]
12. Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Herbert BS; Gellert GC; Hochreiter A; Pongracz K; Wright WE; Zielinska D; Chin AC; Harley CB; Shay JW; Gryaznov SM Oncogene; 2005 Aug; 24(33):5262-8. PubMed ID: 15940257 [TBL] [Abstract][Full Text] [Related]
13. Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. Burchett KM; Yan Y; Ouellette MM PLoS One; 2014; 9(1):e85155. PubMed ID: 24409321 [TBL] [Abstract][Full Text] [Related]
14. Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Shammas MA; Qazi A; Batchu RB; Bertheau RC; Wong JY; Rao MY; Prasad M; Chanda D; Ponnazhagan S; Anderson KC; Steffes CP; Munshi NC; De Vivo I; Beer DG; Gryaznov S; Weaver DW; Goyal RK Clin Cancer Res; 2008 Aug; 14(15):4971-80. PubMed ID: 18676772 [TBL] [Abstract][Full Text] [Related]
15. Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton. Mender I; Senturk S; Ozgunes N; Akcali KC; Kletsas D; Gryaznov S; Can A; Shay JW; Dikmen ZG Int J Oncol; 2013 May; 42(5):1709-15. PubMed ID: 23545855 [TBL] [Abstract][Full Text] [Related]
16. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Duus J; Bahar HI; Venkataraman G; Ozpuyan F; Izban KF; Al-Masri H; Maududi T; Toor A; Alkan S Leuk Lymphoma; 2006 Jul; 47(7):1369-78. PubMed ID: 16923571 [TBL] [Abstract][Full Text] [Related]
18. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response. Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691 [TBL] [Abstract][Full Text] [Related]
19. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Shammas MA; Shmookler Reis RJ; Akiyama M; Koley H; Chauhan D; Hideshima T; Goyal RK; Hurley LH; Anderson KC; Munshi NC Mol Cancer Ther; 2003 Sep; 2(9):825-33. PubMed ID: 14555701 [TBL] [Abstract][Full Text] [Related]
20. The effect of telomerase template antagonist GRN163L on bone-marrow-derived rat mesenchymal stem cells is reversible and associated with altered expression of cyclin d1, cdk4 and cdk6. Tokcaer-Keskin Z; Dikmen ZG; Ayaloglu-Butun F; Gultekin S; Gryaznov SM; Akcali KC Stem Cell Rev Rep; 2010 Jun; 6(2):224-33. PubMed ID: 20180048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]